Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
141
resultados
Última actualización
25/07/2025 [07:09:00]
Resumen de: US2025237642A1
Methods for predicting mutations in viruses, such as Coronaviruses, upon exposure to antiviral drugs, are disclosed. Mutated, non-naturally occurring viruses including those mutations, and methods of treatment with drugs that remain effective against the mutated viruses, are disclosed. These predictive methods can be useful in properly treating Covid patients with small molecule antiviral compounds that are effective against the particular SARS-COV-2 variant infecting the patient.
Resumen de: US2025235529A1
The present disclosure provides compositions of adjuvanted SARS-CoV-2 vaccines and their use to prevent and manage Covid-19 infection, including host hyperinflammatory responses to infection, including long term symptoms associated with Covid infection.
Resumen de: US2025235530A1
Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.
Resumen de: US2025236920A1
A method of detecting SARS-CoV-2 includes contacting a sample with a primer set and reverse transcription loop-mediated isothermal amplification (RT-LAMP) reagents, which includes calcein, to form a reaction mixture, and amplifying the cDNA by incubating the reaction mixture to amplify the target sequence of the SARS-CoV-2 nucleic acid sequence in the sample. The sample is further assayed with an assay to detect the amplified target sequence of the SARS-CoV-2 nucleic acid sequence, and thereby to detect SARS-CoV-2 in the sample.
Resumen de: US2025236652A1
The present disclosure generally relates to systems and methods for treating and preventing diseases or conditions such as aging, atherosclerosis, obesity, viral disease, etc. These may be treated, according to some embodiments, by activation of an immune response within a subject. In some embodiments, for example, aging may be treated or prevented by removal of senescent cells by the immune system. In some embodiments, atherosclerosis may be treated or prevented by removal of plaque by the immune system. In some embodiments, obesity may be treated by removal of fat cells by the immune system. In some embodiments, viral diseases may be treated by removal of viruses by the immune system. Exemplary viral diseases include diseases caused by SARS-COV-2 and HIV, among others.
Resumen de: US2025236660A1
The disclosure relates in some aspects to methods of treating a subject having post-acute sequelae of COVID-19 (PASC), sometimes also known as “long COVID.” Also provided are pharmaceutical combinations for treating a subject having PASC, such as using one or more antiviral agents and one or more antibodies, as well as kits used with disclosed pharmaceutical combinations and in disclosed methods.
Resumen de: US2025236912A1
The present invention relates to the field of RNA editing using novel Cast 3 polypeptides in a CRISPR/Cas13 system. The novel Cast 3 polypeptides have collateral, or ‘trans’ cleavage activity and can be utilised in a nucleic acid detection systems, such as a Cast 3 SARS-CoV-2-based detection assay.
Resumen de: US2025235452A1
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.
Resumen de: US2025236913A1
The present invention relates to the diagnostic of inflammatory diseases. The inventors described methods using NET biomarkers as diagnostic biomarkers for inflammatory diseases. COVID-19, Lupus or mCRC are used here as illustrative models for investigating an inflammatory disease. Examples in highlighting variation of the respective correlation of NET biomarkers in this invention rely on the determination of the NET main constituents: (i), DNA as determined by examining the amount of circulating DNA (cirDNA) that corresponds to the amount of NET as being degradation by-products that are released into the circulation; (ii) NE; and (iii), MPO; as well as the detection of a blood compound being indirectly associated to NET formation like the anti-cardiolipin auto-antibody. The invention provides threshold values of NE, MPO, cir-nDNA, and cir-mtDNA blood concentrations and of MNR that can be combined to diagnose/screen individuals. Thus the invention relates to a method for diagnosing a subject for an inflammatory disease comprising the steps of i) determining in a sample obtained from the subject the level of at least one marker selected in the group consisting in NET protein markers, cir-nDNA, cir-mtDNA and/or a cir-DNA fragmentation index.
Resumen de: AU2023341167A1
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.
Resumen de: US2025228927A1
Disclosed are a recombinant fusion protein derived from an HR region of an S2 protein of SARS-CoV-2 and an application of the recombinant fusion protein. The SARS-CoV-2 recombinant fusion protein is a recombinant fusion protein obtained by linking two membrane fusion-related conserved amino acid sequences HR1 and HR2 of the SARS-CoV-2 membrane protein S2 protein by means of a linking peptide. The recombinant fusion protein can be induced and expressed in Escherichia coli, has high expression quantity, and is easy to purify. The SARS-CoV-2 recombinant fusion protein provided by the present invention can form and maintain a stable dimer structure, simulates the conformation of a SARS-CoV-2 membrane fusion intermediate state, can be used as a detection raw material for detecting a SARS-CoV-2 membrane fusion process, has good anti-SARS-CoV-2 activity and good immunogenicity, and has a wide application prospect in the fields of development of drugs for preventing or treating SARS-CoV-2 proteins and development of SARS-CoV-2 vaccines and anti-SARS-CoV-2 antibodies.
Resumen de: US2025228931A1
Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
Resumen de: US2025228929A1
Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 Omicron variant spike protein or portion thereof, or a derivative thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 Omicron variant spike protein ectodomain or a derivative thereof, and NDV F protein transmembrane and cytoplasmic domains. Further, described herein are immunogenic compositions comprising a recombinant NDV(s). The recombinant NDVs and immunogenic compositions are useful for the immunizing against SARS-CoV-2 as well as the prevention of COVID-19.
Resumen de: US2025228808A1
Compositions and methods for inhibiting coronavirus infection and for treating subjects already infected with a coronavirus such as the SARS-COV-2 virus that causes COVID-19. The compositions and methods are also useful for reducing the risk of developing severe CO VID-19 if a subject becomes infected with the SARS-COV-2 virus. The compositions and methods reduce viral load and reduce the time to reach clinical resolution in COVID-19 patients.
Resumen de: US2025228882A1
Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.
Resumen de: US2025228930A1
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.
Resumen de: GB2637234A
Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-nucleated or mature cells. The methods can also include assessing the eSTBs for coronavirus susceptible markers. Also disclosed are compositions and methods (i) for inducing the differentiation of eSTBs and mature STBs from trophoblast stem cells (TSCs), (ii) for inducing the differentiation of TSCs from EPSCs, primed and naïve stem cells, pre-implantation embryos, placental stem cells, and iPSCs, and (ii) for producing TSCs by reprogramming non-trophoblast cells. The disclosed compositions and methods can be used for producing large quantities of coronavirus particles, including human, non-human, and variant coronavirus particles for virus production, the vaccine inductry, disease modeling studies, screening and evaluation of antiviral reagents, compound candidates, testing kits, and evaluation of clinical therapies.
Resumen de: AU2023336178A1
The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS- CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.
Resumen de: EP4585226A1
The present invention provides a pharmaceutical composition for use in therapy or prevention of the novel coronavirus (SARS-CoV-2) disease 2019 (COVID-19), the composition containing an IL-10 inhibitor.
Resumen de: EP4585687A1
It is an object of the present invention to provide an antibody against coronavirus (SARS-CoV-2) variants. It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. The present invention provides an antibody or antigen-binding fragment thereof that binds to the spike protein of the coronavirus and has the ability to neutralize coronaviruses, including the Omicron variant, and a pharmaceutical composition for the prevention or treatment of coronavirus infection, which contains the antibody or an antigen-binding fragment thereof.
Resumen de: KR102832944B1
본 발명은 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물에 관한 것이다.
Resumen de: JP2024038003A
To provide antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein, and methods of using such antibodies and fragments for treating or preventing viral infections.SOLUTION: The present disclosure provides a neutralizing human antibody- binding protein that binds specifically to SARS-CoV-2-S, such as an antibody and an antigen-binding fragment thereof.SELECTED DRAWING: None
Resumen de: KR20250106684A
본 발명은 SARS-CoV-2의 외피 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도에 관한 것으로, 구체적으로 본 발명은 SARS-CoV-2 바이러스의 외피 단백질(envelope protein)에 특이적으로 결합하는 DNA 앱타머, 상기 DNA 앱타머를 유효성분으로 포함하는 SARS-CoV-2 바이러스의 외피 단백질(envelope protein) 검출용 조성물, SARS-CoV-2 바이러스 검출용 키트, SARS-CoV-2 바이러스 검출용 칩 또는 마이크로어레이 및 상기 DNA 앱타머를 이용한 SARS-CoV-2 바이러스의 외피 단백질 검출 방법에 관한 것이다. 또한 본 발명은 본 발명의 DNA 앱타머를 유효성분으로 포함하는, 코로나바이러스 감염증-19 진단용 조성물, 코로나바이러스 감염증-19의 예방 또는 치료용 약학적 조성물, SARS-CoV-2 바이러스의 외피 단백질에 특이적 결합하는 DNA 앱타머의 제조방법 및 코로나바이러스 감염증-19의 진단에 필요한 정보를 제공하는 방법에 관한 것이다.
Nº publicación: AU2024214518A1 10/07/2025
Solicitante:
CEPHEID
CEPHEID
Resumen de: AU2024214518A1
The present disclosure provides a set of primers and optional probes for identifying the presence of α-coronavirus, β-coronavirus, SARS-CoV-2, adenovirus, Chlamydia pneumoniae, Influenza A, Influenza B, metapneumovirus, rhinovirus/enterovirus, mycoplasma, Bordetella spp., parainfluenza, and respiratory syncytial virus (RSV), which can be included with (e.g., in at kit) or in a cartridge for automated detection of these pathogens by nucleic acid amplification. This disclosure also provides related detection methods, as well as cartridges, systems, and kits useful in such methods.
BOPI
Sede Electrónica
